10x Genomics, Inc. Financials | Key Metrics & Investor Analysis

The financial statements for 10x Genomics, Inc. (TXG) provide a snapshot of revenue trends, balance-sheet strength, and cash flow quality. Reviewing these together helps investors evaluate earnings durability, capital structure, and whether operating cash flow supports long-term business growth.

See stock fair value and complete historical financials—premium unlocks deeper tables and metrics.

Financial Statements

TXG valuation comparisons with competitors

Compare More →

Frequently Asked Questions

What are 10x Genomics, Inc.'s latest financial results?

Review 10x Genomics, Inc.'s latest balance sheet, income statement, and cash flow to understand its profitability, revenue trends, and financial health. These metrics are essential for evaluating short-term performance and long-term stability.

How has 10x Genomics, Inc.'s revenue and net income changed over time?

Analyzing historical revenue and net income shows growth trends and business performance. Consistent growth indicates operational strength, while declines may signal challenges that investors should consider.

What is 10x Genomics, Inc.'s cash flow situation and liquidity?

Cash flow statements reveal how 10x Genomics, Inc. generates and uses cash. Strong operating cash flow and sufficient liquidity suggest the company can fund operations, pay dividends, and handle debt effectively.

How does 10x Genomics, Inc.'s financial performance compare to industry peers?

Comparing key metrics like revenue growth, profit margins, and debt levels with competitors helps investors assess whether 10x Genomics, Inc. is outperforming or lagging within its sector.

Are 10x Genomics, Inc.'s financial statements showing sustainable profitability?

By analyzing margins, ROE, ROIC, and cash generation over multiple periods, investors can evaluate whether 10x Genomics, Inc.'s profits are repeatable and supported by strong fundamentals.